These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1719718)

  • 21. Pseudomonas aeruginosa-specific IgG1 and IgG2 subclasses in enhancement of pulmonary clearance following passive immunisation in the rat.
    Dunkley ML; Rajyaguru S; McCue A; Cripps AW; Kyd JM
    FEMS Immunol Med Microbiol; 2003 Oct; 39(1):37-44. PubMed ID: 14556994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Passive immunization against Pseudomonas aeruginosa recombinant PilA in a murine burn wound model.
    Mousavi M; Behrouz B; Irajian G; Mahdavi M; Korpi F; Motamedifar M
    Microb Pathog; 2016 Dec; 101():83-88. PubMed ID: 27836762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pseudomonas aeruginosa. Vaccines and immunotherapy.
    Pennington JE
    Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunoprophylaxis and immunotherapy of infection caused by Pseudomonas aeruginosa: research results and prospects].
    Stanislavskiĭ ES; Joó I
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Jul; (7):22-31. PubMed ID: 6414198
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of anti-OprF-OprI immunoglobulin on APACHE II score in a porcine two-hit model of hemorrhagic shock/resuscitation and pseudomonas aeruginosa sepsis.
    Haberstroh J; Gilleland HE; von Specht BU
    Eur Surg Res; 2005; 37(5):265-73. PubMed ID: 16374008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies raised against divalent type b flagellin and pilin provide effective immunotherapy against Pseudomonas aeruginosa infection of mice with burn wounds.
    Saffari M; Behbood S; Irajian G; Khorshidi A; Moniri R; Behrouz B
    Biologicals; 2017 Jan; 45():20-26. PubMed ID: 27836582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model.
    Barnea Y; Carmeli Y; Gur E; Kuzmenko B; Gat A; Neville LF; Eren R; Dagan S; Navon-Venezia S
    Plast Reconstr Surg; 2006 Jun; 117(7):2284-91. PubMed ID: 16772930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [An O-antigen study of Pseudomonas aeruginosa from serological group O11].
    Bekina KE; Ivanova NI
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Jun; (6):18-20. PubMed ID: 1699370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model.
    Thomsen K; Christophersen L; Bjarnsholt T; Jensen PØ; Moser C; Høiby N
    J Cyst Fibros; 2016 Mar; 15(2):171-8. PubMed ID: 26303991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F.
    Hancock RE; Mutharia LM; Mouat EC
    Eur J Clin Microbiol; 1985 Apr; 4(2):224-7. PubMed ID: 2408887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The first clinical trial of immuno's experimental Pseudomonas aeruginosa flagellar vaccines.
    Crowe BA; Enzersberger O; Schober-Bendixen S; Mitterer A; Mundt W; Livey I; Pabst H; Kaeser R; Eibl M; Eibl J
    Antibiot Chemother (1971); 1991; 44():143-56. PubMed ID: 1801633
    [No Abstract]   [Full Text] [Related]  

  • 33. The peculiarities of Pseudomonas aeruginosa resistance to antibiotics and prevalence of serogroups.
    Gailiene G; Pavilonis A; Kareiviene V
    Medicina (Kaunas); 2007; 43(1):36-42. PubMed ID: 17297282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serological typing of Pseudomonas aeruginosa.
    Madhubala ; Shriniwas
    Indian J Med Res; 1979 Jun; 69():926-32. PubMed ID: 112052
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.
    Shime N; Sawa T; Fujimoto J; Faure K; Allmond LR; Karaca T; Swanson BL; Spack EG; Wiener-Kronish JP
    J Immunol; 2001 Nov; 167(10):5880-6. PubMed ID: 11698464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experimentally determined safety and immunological activity of vaccine based on antigens isolated from Pseudomonas aeruginosa in medium K-4].
    Nuriddinova NR; Sheremet'ev NN; Ivanova LE; Garib FIu; Iskhakova KhI
    Zh Mikrobiol Epidemiol Immunobiol; 2005; (3):57-60. PubMed ID: 16028515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Lang AB; Schaad UB; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Cryz SJ
    J Pediatr; 1995 Nov; 127(5):711-7. PubMed ID: 7472821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Basis for the potential production of immune preparations against Pseudomonas aeruginosa from the blood of convalescent burn patients].
    Povstianoĭ NE; Kolker II; Nazarchuk LV; Fedorovskaia EA; Litovchenko PP
    Gematol Transfuziol; 1984 Jul; 29(7):56-8. PubMed ID: 6205938
    [No Abstract]   [Full Text] [Related]  

  • 39. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
    Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
    J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.